Global Marijuana Market Could Reach $18.6 Billion by 2027: UN Report

Dec.12.2022
Global Marijuana Market Could Reach $18.6 Billion by 2027: UN Report
UNCTAD predicts the global cannabis market could reach $18.6 billion by 2027, if key issues are addressed.

According to a comprehensive industry report by the United Nations Conference on Trade and Development (UNCTAD), the global cannabis market could reach $18.6 billion by 2027 if countries around the world take action to clarify the legal status of marijuana and address other key issues.


According to a report from Hemp Today, citing data from Krungsri Research Intelligence, a research unit under the Bank of Ayudhya based in Bangkok, the market value of cannabis in the next five years could double the estimated $4.7 billion in 2020.


The report of the trade development conference covers:


Information: The authors of the report suggest that the cannabis industry needs increased transparency, including public data on all cannabis production outputs, specific country/region data, and pricing information. "At an international level, it is clear that the availability and accessibility of information needs to be improved. Efforts should be made to improve the current state of information on all aspects of this commodity.


The report suggests that other categories should be included, such as hemp seeds, hemp seed oil, hemp seed products, cannabis resin, and essential oils.


Sustainability: The report also indicates that environmental and social factors are "key to the success of any cannabis-related policy" and should therefore be considered within a broader legal and regulatory framework.


The report states that "to ensure the sustainable development of the global cannabis industry, cannabis cultivation can provide environmental benefits that can be taken into account in policies aimed at mitigating the impacts of climate change and restoring healthy ecosystems.


The report indicates that cannabis cultivation could potentially maximize land use and also increase income for farmers and rural communities, particularly in developing countries.


Industry Strategy: The Trade and Development Conference suggests that most regions of the world should consider a comprehensive cannabis cultivation strategy, stating that "given the relatively small size of the cannabis market and its inherent economic constraints, this approach is more viable." The document also notes that the comprehensive cultivation approach may lead to business opportunities in both primary and secondary markets, and that cannabis cultivation can further be monetized through the integration of voluntary carbon credit programs.


This 84-page report outlines the steps that the government can take to utilize the economic and social potential of marijuana, categorizes industrial hemp by output type, and demonstrates how the derivative products of this cannabis sub-industry are reflected in trade statistics.


According to the report, the cannabis value chain can promote growth in rural areas and contribute to manufacturing and food processing industries. However, in order to fully exploit this potential, countries may have to take specific actions. This represents the first international governmental organization document promoting the use of industrial hemp.


The report also addresses the legal issues surrounding marijuana. It notes that clarifying the legal status of marijuana as a non-narcotic substance is the first step the government should take in order to minimize legal and financial risks for producers.


The report suggests that all countries should permit the cultivation of non-intoxicating C. Sativa L. strains, despite the possibility of strict government control. Additionally, a method that promotes overall production and usage, rather than field THC thresholds, should be adopted for the benefit of the final product.


Alternatively, legislators could increase the THC threshold for "field" crops to the scientifically recognized non-toxic level. The report states, "This would increase the variety of strains available for use in the cannabis production chain, thus actually increasing the likelihood of cultivating strains that are best suited to specific environmental conditions and characteristics.


The report also suggests that additional production restrictions imposed by the regulatory framework must be identified and a regional cooperation strategy should be developed to establish a viable and sustainable value chain.


2FIRSTS will continue to follow and report on this topic, with future updates available on the "2FIRSTSAPP." Scan the QR code below to download the app.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

FDA and IKE Tech Hold Formal Listening Session on Youth Access and Illicit ENDS Products
FDA and IKE Tech Hold Formal Listening Session on Youth Access and Illicit ENDS Products
U.S. Food and Drug Administration’s Center for Tobacco Products held a formal listening session with IKE Tech LLC to discuss youth prevention at the point of use for ENDS products, the circulation of illicit products in the supply chain, and the regulatory treatment of software in tobacco products.
Apr.10 by 2FIRSTS.ai
Disposable Vape Ban Shifts Purchasing Formats as UK Vape Volume Falls 10.3%
Disposable Vape Ban Shifts Purchasing Formats as UK Vape Volume Falls 10.3%
Data from convenience insight agency Talysis shows that the value of tobacco, vapes and smoking alternatives in the independent convenience sector fell by 4.4% in the first quarter of 2026, while volume fell by 7.8%. The vaping subcategory declined by 3.9% in value and 10.3% in volume over the same period. Talysis said the impact of the disposable vape ban continues to pressure turnover and footfall.
May.08 by 2FIRSTS.ai
FDA Tobacco Center Plans Faster Review Process for Certain Supplemental PMTAs
FDA Tobacco Center Plans Faster Review Process for Certain Supplemental PMTAs
FDA Center for Tobacco Products Acting Director Bret Koplow issued a statement on May 7 outlining new steps to accelerate tobacco product premarket application review. The statement said CTP reduced the backlog of applications by approximately 70% in 2025 and that there is no longer a queue for PMTAs pending acceptance review.
May.09 by 2FIRSTS.ai
FDA Commissioner Marty Makary Resigns After Opposing Trump Administration’s Flavored Vape Push
FDA Commissioner Marty Makary Resigns After Opposing Trump Administration’s Flavored Vape Push
FDA Commissioner Marty Makary resigned on May 12 after opposing the Trump administration’s push to authorize fruit-flavored vaping products, according to reporting by The New York Times. Makary reportedly objected over concerns that flavored vapes could attract young people and refused to support broader approvals.
News
May.13
California Bill Would Let Schools Include Nicotine in Student-Athlete Drug Screens
California Bill Would Let Schools Include Nicotine in Student-Athlete Drug Screens
California lawmakers are advancing a bill that would allow schools with existing student-athlete drug testing programs to include nicotine in those screenings.
Apr.09 by 2FIRSTS.ai
Acting CTP Director Says FDA Cut Premarket Tobacco Application Backlog by About 70% Over the Past Year
Acting CTP Director Says FDA Cut Premarket Tobacco Application Backlog by About 70% Over the Past Year
FDA Center for Tobacco Products Acting Director Bret Koplow said at the American Tobacco and Nicotine Forum that the agency has reduced its premarket tobacco application backlog by about 70% over the past year and eliminated the acceptance queue. He said FDA has reviewed about 27 million applications, but only a small number have been authorized, mainly because most submissions lacked the scientific data needed to demonstrate public health benefits.
Apr.23 by 2FIRSTS.ai